| Code | CSB-RA007916MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of REGN9933, targeting coagulation factor XI (F11; FXI)—a plasma serine protease zymogen that amplifies thrombin generation through the intrinsic coagulation pathway. FXI can be activated by factor XIIa (FXIIa) via contact activation or by thrombin in feedback amplification, linking upstream pathway triggers to sustained clot propagation. Because FXI is viewed as more critical for pathologic thrombosis than for baseline hemostasis, FXI-targeting tools are widely used to dissect antithrombotic mechanisms with the goal of minimizing bleeding liability.
REGN9933 (often specified as REGN9933A2) is a monoclonal antibody that binds the FXI apple 2 (A2) domain and is designed to selectively block FXI activation by FXIIa (while not broadly inhibiting thrombin-mediated activation), enabling pathway-selective interrogation of contact-system–driven thrombosis. It has been evaluated in clinical studies for venous thromboembolism prevention (including postoperative settings) and is being positioned as a potential option for patients where bleeding risk is a key concern, supporting translational research into how FXIIa→FXI activation contributes to thrombotic disease and how selective FXI modulation impacts efficacy–safety balance.
There are currently no reviews for this product.